Is renoprotection with RAAS blockade a failed paradigm? Have we learnt any lessons so far?

International Journal of Clinical Practice

Volumn 64, Issue 10, 2010, Pages 1341-1346

  Onuigbo, M A C ^a,b  

^a MAYO CLINIC   (United States)

^b Mayo Health System Practice Based Research Network MHS PBRN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ANGIOTENSIN RECEPTOR ANTAGONIST; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LOSARTAN; RAMIPRIL;

ACUTE KIDNEY FAILURE; AGE; CHRONIC KIDNEY DISEASE; CREATININE BLOOD LEVEL; DEMENTIA; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DRUG WITHDRAWAL; EXCRETION; FAILURE TO THRIVE; GENDER; HEART FAILURE; HEART PROTECTION; HEART SURGERY; HYPERTENSION; HYPOTENSION; LYMPHOMA; NEPHROTOXICITY; PRIORITY JOURNAL; PROTEINURIA; RACE; RENAL PROTECTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SEPSIS; SHOCK;

ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CHRONIC DISEASE; DIABETIC NEPHROPATHIES; DISEASE PROGRESSION; DRUG THERAPY, COMBINATION; GLOMERULAR FILTRATION RATE; HUMANS; KIDNEY DISEASES; KIDNEY FAILURE, CHRONIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RENIN-ANGIOTENSIN SYSTEM; TREATMENT FAILURE;

EID: 77955805254     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2010.02448.x     Document Type: Review

References (35)

1. Ondetti MA, Rubin B, Cushman DW. Design of specific inhibitors of angiotensin-converting enzyme: new class of orally active antihypertensive agents. Science 1977; 196: 441-4.
2. Onuigbo M. Angiotensin II receptor antagonists: what future? South Med J 1998; 91: 794-6.
3. Heart Outcomes Prevention Evaluation Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICROHOPE substudy. Lancet 2000; 355: 253-9. Erratum in: Lancet 2000;356(9232):860.
4. Brenner BM, Cooper ME, de Zeeuw D et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861-9.
5. Pfeffer MA, Swedberg K, Granger CB et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-overall programme. Lancet 2003; 362: 759-66.
6. Onuigbo M, Weir MR. Evidence-based treatment of hypertension in patients with diabetes mellitus. Diabetes Obes Metab 2003; 5: 13-26.
7. Lewis EJ, Hunsicker LG, Bain RP et al.. The effect of angiotensinconverting enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 1993; 329:1456-1462. Erratum in: N Engl J Med 330(2):152.
8. Ruggenenti P, Perna A, Gherardi G et al. Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with nonnephrotic proteinuria. Lancet 1999; 354: 359-64.
9. Lewis EJ, Hunsicker LG, Clarke WR et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345: 851-60.
10. Rossing K, Jacobsen P, Pietraszek L, Parving HH. Renoprotective effects of adding angiotensin II receptor blocker to maximal recommended doses of ACE inhibitor in diabetic nephropathy: a randomized double-blind crossover trial. Diabetes Care 2003; 26: 2268-74.
11. Carter BL, Malone DC, Ellis SL, Dombrowski RC. Antihypertensive drug utilization in hypertensive veterans with complex medication profiles. J Clin Hypertens (Greenwich) 2000; 2: 172-80.
12. Cooper H, Patall EA. The relative benefits of meta-analysis conducted with individual participant data versus aggregated data. Psychol Methods 2009; 14: 165-76.
13. Ameringer S, Serlin RC, Ward S. Simpson's Paradox and experimental research. Nurs Res 2009; 58: 123-7.
14. Riley RD, Lambert PC, Staessen JA et al. Meta-analysis of continuous outcomes combining individual patient data and aggregate data. Statist Med 2008; 27: 1870-93.
15. Tsalamandris C, Allen TJ, Gilbert RE et al. Progressive decline in renal function in diabetic patients with and without albuminuria. Diabetes 1994; 43: 649-55.
16. Jones CA, Krolewski AS, Rogus J, Xue JL, Collins A, Warram JH. Epidemic of end-stage renal disease in people with diabetes in the United States population: Do we know the cause? Kidney Int 2005; 67: 1684-91.
17. Centers for Disease Control and Prevention (CDC). Prevalence of chronic kidney disease and associated risk factors - United States, 1999-2004. MMWR Morb Mortal Wkly Rep 2007; 56:161-5.
18. Hsu CY, McCulloch CE, Fan D, Ordoñez JD, Chertow GM, Go AS. Community-based incidence of acute renal failure. Kidney Int 2007; 72: 208-12. Epub 2007 May 16.
19. Suissa S, Hutchinson T, Brophy JM, Kezouh A. ACE-inhibitor use and the long-term risk of renal failure in diabetes. Kidney Int 2006; 69: 913-9.
20. Onuigbo MA. Does concurrent renin-angiotensin-aldosterone blockade in (older) chronic kidney disease patients play a role in the acute renal failure epidemic in US hospitalized patients? - Three cases of severe acute renal failure encountered in a northwestern Wisconsin Nephrology practice. Hemodial Int. 2009; 13(Suppl. 1): S24-9.
21. Casas JP, Chua W, Loukogeorgakis S et al. Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis. Lancet 2005; 366: 2026-33.
22. Svensson P, de Faire U, Sleight P, Yusuf S, Ostergren J. Comparative effects of ramipril on ambulatory and office blood pressures. A HOPE substudy. Hypertension 2001; 38: e28-32.
23. Onuigbo MA, Onuigbo NT. Late-onset renal failure from angiotensin blockade (LORFFAB) in 100 CKD patients. Int Urol Nephrol 2008; 40: 233-9. Epub 2008 Jan 15.
24. Onuigbo MAC. Reno-prevention vs. reno-protection: a critical re-appraisal of the evidence-base from the large RAAS blockade trials after ONTARGET - A call for more circumspection. QJM 2009; 102: 155-67. Epub ahead of print Jan 5 2009.
25. Onuigbo MAC. An analytical review of the evidence-base for renoprotection from the large RAAS blockade trials after ONTARGET. Re-visitation of the potential for iatrogenic renal failure with RAAS blockade ? A call for caution. Nephron Clin Pract 2009; 113: c63-9, Epub 2009 Jul 14.
26. ONTARGET Investigators, Yusuf S, Teo KK, Pogue J et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008; 358: 1547-59. Epub 2008 Mar 31.
27. Mann JF, Schmieder RE, McQueen M, et al. ONTARGET investigators. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet 2008; 372:547-53.
28. Kunz R, Friedrich C, Wolbers M, Mann JF. Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease. Ann Intern Med 2008; 148:30-48. Epub 2007 Nov 5.
29. Onuigbo MA, Onuigbo NT. Late onset renal failure from angiotensin blockade (LORFFAB): a prospective thirty-month Mayo Health System clinic experience. Med Sci Monit 2005; 11:CR462-9. Epub 2005 Sep 26.
30. Rahman M, Pressel S, Davis BR et al. Renal outcomes in highrisk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch Intern Med 2005; 165: 936-46.
31. Onuigbo MA. ALLHAT findings revisited in the context of subsequent analyses, other trials, and meta-analyses. Arch Intern Med 2009; 169: 1810.
32. Ahmed AK, Kamath NS, El Kossi M, El Nahas AM. The impact of stopping inhibitors of the renin-angiotensin system in patients with advanced chronic kidney disease. Nephrol Dial Transplant 2009; DOI: 10.1083/ndt/gfp 511v1-gfp511.
33. Breyer JA. Diabetic nephropathy in insulin-dependent patients. Am J Kidney Dis 1992; 20: 533-47.
34. Onuigbo MA. The natural history of chronic kidney disease revisited - a 72-month Mayo Health System Hypertension Clinic practice-based research network prospective report on end-stagerenal disease and death rates in 100 high-risk chronic kidney disease patients: a call for circumspection. Adv Perit Dial 2009; 25: 85-8.
35. Ishani A, Xue JL, Himmelfarb J et al. Acute kidney injury increases risk of ESRD among elderly. J Am Soc Nephrol 2009; 20: 223-8. Epub 2008 Nov 19.